Amalgamated Bank Sells 34,385 Shares of Organon & Co. (NYSE:OGN)

Amalgamated Bank reduced its stake in Organon & Co. (NYSE:OGN - Free Report) by 29.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 80,530 shares of the company's stock after selling 34,385 shares during the quarter. Amalgamated Bank's holdings in Organon & Co. were worth $1,541,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of OGN. Mercer Global Advisors Inc. ADV lifted its holdings in Organon & Co. by 1.8% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 31,086 shares of the company's stock worth $674,000 after purchasing an additional 546 shares during the last quarter. Ballentine Partners LLC lifted its holdings in Organon & Co. by 3.0% during the 2nd quarter. Ballentine Partners LLC now owns 19,105 shares of the company's stock worth $395,000 after purchasing an additional 552 shares during the last quarter. Bill Few Associates Inc. lifted its holdings in Organon & Co. by 5.4% during the 2nd quarter. Bill Few Associates Inc. now owns 12,218 shares of the company's stock worth $253,000 after purchasing an additional 621 shares during the last quarter. Sippican Capital Advisors lifted its holdings in Organon & Co. by 4.3% during the 3rd quarter. Sippican Capital Advisors now owns 15,230 shares of the company's stock worth $291,000 after purchasing an additional 627 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Organon & Co. by 19.2% during the 2nd quarter. GAMMA Investing LLC now owns 4,036 shares of the company's stock worth $84,000 after purchasing an additional 649 shares during the last quarter. 77.43% of the stock is owned by institutional investors.

Analyst Ratings Changes

OGN has been the subject of several analyst reports. Evercore ISI raised Organon & Co. to a "strong-buy" rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. cut Organon & Co. from a "neutral" rating to an "underweight" rating and lifted their price objective for the company from $18.00 to $20.00 in a report on Friday, September 6th.

Organon & Co. Price Performance

Shares of OGN remained flat at $15.58 during midday trading on Wednesday. The stock had a trading volume of 990,193 shares, compared to its average volume of 2,244,791. Organon & Co. has a one year low of $10.84 and a one year high of $23.10. The company's 50 day moving average price is $18.50 and its two-hundred day moving average price is $20.02. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The company has a market cap of $4.01 billion, a PE ratio of 3.10, a price-to-earnings-growth ratio of 0.73 and a beta of 0.84.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The company's revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.78 EPS. On average, research analysts predict that Organon & Co. will post 3.89 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Tuesday, November 12th will be given a dividend of $0.28 per share. The ex-dividend date is Tuesday, November 12th. This represents a $1.12 dividend on an annualized basis and a yield of 7.19%. Organon & Co.'s dividend payout ratio is currently 22.22%.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.